Skip to main content
Top
Published in: BMC Public Health 1/2012

Open Access 01-12-2012 | Research article

Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study

Authors: Laure Huot, Evelyne Decullier, Karen Maes-Beny, Francois R Chapuis

Published in: BMC Public Health | Issue 1/2012

Login to get access

Abstract

Background

Scientific evidence supports decision-making on the use of implantable medical devices (IMDs) in clinical practice, but IMDs are thought to be far less investigated than drugs. In the USA, studies have shown that approval process of high-risk medical devices was often based on insufficiently robust studies, suggesting that evidence prior to marketing may not be adequate. This study aimed to ascertain level of evidence available for IMDs access to reimbursement in France.

Methods

The objective was to examine the scientific evidence used for IMDs assessment by the French National Authority for Health. We collected all public documents summarising supportive clinical data and opinions concerning IMDs issued in 2008. An opinion qualifies the expected benefit (EB) of the IMD assessed as sufficient or insufficient, and if sufficient, the level of improvement of the expected benefit (IEB) on a scale from major (level I) to no improvement (level V). For each opinion, the study with the highest level of evidence of efficacy data, and its design were collected, or, where no studies were available, any other data sources used to establish the opinion.

Results

One hundred and two opinions were analysed, with 72 reporting at least one study used for assessment (70.6%). When considering the study with the highest level of evidence: 34 were clinical non-comparative studies (47.2%); 29 were clinical comparative studies of which 25 randomised controlled trials (40.3%); 5 were meta-analyses of randomised controlled trials (6.9%); and 4 were systematic literature reviews (5.6%). The opinions were significantly different according to the study design (p < 0.001). The most frequent design for insufficient EB, IEB level V and IEB level IV was a non-comparative study (10/19, 52.6%; 15/24, 62.5%; and 8/15, 53.3%; respectively). For the 30 opinions with no supporting clinical study, 16 (53.3%) were based on an expert-based process, 9 (30.0%) were based on the conclusions of a previous opinion (all concluding IEB level V), and 5 (16.7%) reported no data (concluding insufficient EB for 4 and IEB level V for 1).

Conclusions

This study confirmed that level of evidence of clinical evaluation of IMDs is low and needs to be improved.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maisel WH: Medical device regulation: an introduction for the practicing physician. Ann Intern Med. 2004, 140 (4): 296-302.CrossRefPubMed Maisel WH: Medical device regulation: an introduction for the practicing physician. Ann Intern Med. 2004, 140 (4): 296-302.CrossRefPubMed
2.
go back to reference Monsein LH: Primer on medical device regulation. Part I. History and background. Radiology. 1997, 205 (1): 1-9.CrossRefPubMed Monsein LH: Primer on medical device regulation. Part I. History and background. Radiology. 1997, 205 (1): 1-9.CrossRefPubMed
5.
go back to reference Fuchs VR: New priorities for future biomedical innovations. N Engl J Med. 2010, 363 (8): 704-706. 10.1056/NEJMp0906597.CrossRefPubMed Fuchs VR: New priorities for future biomedical innovations. N Engl J Med. 2010, 363 (8): 704-706. 10.1056/NEJMp0906597.CrossRefPubMed
9.
go back to reference Dhruva SS, Bero LA, Redberg RF: Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. Jama. 2009, 302 (24): 2679-2685. 10.1001/jama.2009.1899.CrossRefPubMed Dhruva SS, Bero LA, Redberg RF: Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. Jama. 2009, 302 (24): 2679-2685. 10.1001/jama.2009.1899.CrossRefPubMed
10.
go back to reference Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH: Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010, 17 (1): 2-7. 10.1097/MJT.0b013e3181ca8105.CrossRefPubMed Kramer DB, Mallis E, Zuckerman BD, Zimmerman BA, Maisel WH: Premarket clinical evaluation of novel cardiovascular devices: quality analysis of premarket clinical studies submitted to the Food and Drug Administration 2000-2007. Am J Ther. 2010, 17 (1): 2-7. 10.1097/MJT.0b013e3181ca8105.CrossRefPubMed
12.
go back to reference Reed SD, Shea AM, Schulman KA: Economic implications of potential changes to regulatory and reimbursement policies for medical devices. J Gen Intern Med. 2008, 23 (Suppl 1): 50-56.CrossRefPubMed Reed SD, Shea AM, Schulman KA: Economic implications of potential changes to regulatory and reimbursement policies for medical devices. J Gen Intern Med. 2008, 23 (Suppl 1): 50-56.CrossRefPubMed
14.
go back to reference Huot L, Decullier E, Aulagner G, Chapuis FR: Medical device evaluation: what are the needs?. Presse Med. 2010, 39 (10): 1097-1098. 10.1016/j.lpm.2010.06.002.CrossRefPubMed Huot L, Decullier E, Aulagner G, Chapuis FR: Medical device evaluation: what are the needs?. Presse Med. 2010, 39 (10): 1097-1098. 10.1016/j.lpm.2010.06.002.CrossRefPubMed
16.
go back to reference Sedrakyan A, Marinac-Dabic D, Normand SL, Mushlin A, Gross T: A framework for evidence evaluation and methodological issues in implantable device studies. Med Care. 2010, 48 (6 Suppl): S121-S128.CrossRefPubMed Sedrakyan A, Marinac-Dabic D, Normand SL, Mushlin A, Gross T: A framework for evidence evaluation and methodological issues in implantable device studies. Med Care. 2010, 48 (6 Suppl): S121-S128.CrossRefPubMed
17.
go back to reference Ramsey SD, Luce BR, Deyo R, Franklin G: The limited state of technology assessment for medical devices: facing the issues. Am J Manag Care. 1998, 4: SP188-SP199.PubMed Ramsey SD, Luce BR, Deyo R, Franklin G: The limited state of technology assessment for medical devices: facing the issues. Am J Manag Care. 1998, 4: SP188-SP199.PubMed
18.
go back to reference Hines JZ, Lurie P, Yu E, Wolfe S: Left to their own devices: breakdowns in United States medical device premarket review. PLoS Med. 2010, 7 (7): e1000280-10.1371/journal.pmed.1000280.CrossRefPubMedPubMedCentral Hines JZ, Lurie P, Yu E, Wolfe S: Left to their own devices: breakdowns in United States medical device premarket review. PLoS Med. 2010, 7 (7): e1000280-10.1371/journal.pmed.1000280.CrossRefPubMedPubMedCentral
19.
go back to reference Garber AM: Modernizing device regulation. N Engl J Med. 2010, 362 (13): 1161-1163. 10.1056/NEJMp1000447.CrossRefPubMed Garber AM: Modernizing device regulation. N Engl J Med. 2010, 362 (13): 1161-1163. 10.1056/NEJMp1000447.CrossRefPubMed
22.
go back to reference Konstam MA, Pina I, Lindenfeld J, Packer M: A device is not a drug. J Card Fail. 2003, 9 (3): 155-157. 10.1054/jcaf.2003.45.CrossRefPubMed Konstam MA, Pina I, Lindenfeld J, Packer M: A device is not a drug. J Card Fail. 2003, 9 (3): 155-157. 10.1054/jcaf.2003.45.CrossRefPubMed
23.
go back to reference Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Jama. 2003, 290 (12): 1624-1632. 10.1001/jama.290.12.1624.CrossRefPubMed Tunis SR, Stryer DB, Clancy CM: Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. Jama. 2003, 290 (12): 1624-1632. 10.1001/jama.290.12.1624.CrossRefPubMed
24.
go back to reference Black N: Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996, 312 (7040): 1215-1218. 10.1136/bmj.312.7040.1215. Clinical research edCrossRefPubMedPubMedCentral Black N: Why we need observational studies to evaluate the effectiveness of health care. BMJ. 1996, 312 (7040): 1215-1218. 10.1136/bmj.312.7040.1215. Clinical research edCrossRefPubMedPubMedCentral
25.
go back to reference Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342 (25): 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342 (25): 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral
26.
go back to reference Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, et al: Postmarket evaluation of breakthrough technologies. Am Heart J. 2008, 156 (2): 201-208. 10.1016/j.ahj.2008.01.036.CrossRefPubMed Rao SV, Califf RM, Kramer JM, Peterson ED, Gross TP, Pepine CJ, Williams DO, Donohoe D, Waksman R, Mehran R, et al: Postmarket evaluation of breakthrough technologies. Am Heart J. 2008, 156 (2): 201-208. 10.1016/j.ahj.2008.01.036.CrossRefPubMed
27.
go back to reference Mehran R, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV: Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation. 2004, 109 (25): 3073-3077. 10.1161/01.CIR.0000134694.78653.B6.CrossRefPubMed Mehran R, Leon MB, Feigal DA, Jefferys D, Simons M, Chronos N, Fogarty TJ, Kuntz RE, Baim DS, Kaplan AV: Post-market approval surveillance: a call for a more integrated and comprehensive approach. Circulation. 2004, 109 (25): 3073-3077. 10.1161/01.CIR.0000134694.78653.B6.CrossRefPubMed
28.
go back to reference Raab GG, Parr DH: From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology–part 1: issues in medical device assessment. J Am Coll Radiol. 2006, 3 (9): 694-702. 10.1016/j.jacr.2006.02.005.CrossRefPubMed Raab GG, Parr DH: From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology–part 1: issues in medical device assessment. J Am Coll Radiol. 2006, 3 (9): 694-702. 10.1016/j.jacr.2006.02.005.CrossRefPubMed
29.
go back to reference Dhalla IA, Garner S, Chalkidou K, Littlejohns P: Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care. 2009, 25 (3): 272-280. 10.1017/S026646230999002X.CrossRefPubMed Dhalla IA, Garner S, Chalkidou K, Littlejohns P: Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research. Int J Technol Assess Health Care. 2009, 25 (3): 272-280. 10.1017/S026646230999002X.CrossRefPubMed
Metadata
Title
Medical device assessment: scientific evidence examined by the French national agency for health – a descriptive study
Authors
Laure Huot
Evelyne Decullier
Karen Maes-Beny
Francois R Chapuis
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2012
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/1471-2458-12-585

Other articles of this Issue 1/2012

BMC Public Health 1/2012 Go to the issue